Citations

Clear

6274 citation(s) found for "To, Andrew".

EphA2 Is a Lung Epithelial Cell Receptor for Pneumocystis β-Glucans
Kottom, Theodore J. , Schaefbauer, Kyle, Carmona, Eva M. , Carmona, Eva M , Kottom, Theodore J , Limper, Andrew H.

Mayo Clinic

The Journal of Infectious Diseases | July 20, 2021 | Volume: 225 | Issue: 3 | Pages: 525-530

10.1093/infdis/jiab384 | PMID 34289046 Get It

Abstract Pneumocystis species interaction with myeloid cells is well known, especially in macrophages; however, how the organism binds to lung epithelial cells is incompletely understood. Ephrin type-A receptor 2 (EphA2) has been previously identified as a lung epithelial pattern recognition receptor that binds to fungal β-glucans. Herein, we also report that EphA2 can also bind Pneumocystis β-glucans, both in isolated forms and also on exposed surfaces of the organism. Furthermore, binding of Pneumocystis β-glucans resulted in phosphorylation of the EphA2 receptor, which has been shown to be important for downstream proinflammatory response. Indeed, we also show that interleukin 6 cytokine is significantly increased when lung epithelial cells are exposed to Pneumocystis β-glucans, and that this response could be blocked by preincubation with a specific antibody to EphA2. Our study presents another Pneumocystis lung epithelial cell receptor with implications for initial colonization and possible therapeutic intervention.
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
Guidon, Amanda C. , Burton, Leeann B , Chwalisz, Bart K. , Hillis, James , Schaller, Teilo , Amato, Anthony A., Warner, Allison Betof , Cho, Tracey , Clardy, Stacey , Dietrich, Jörg , Dougan, Michael , Doughty, Christopher , Dubey, Divyanshu , Guptill, Jeffrey T. , Johnson, Douglas B. , Juel, Vern C. , Kadish, Robert , Kolb, Noah , LeBoeuf, Nicole R. , Linnoila, Jenny, Mammen, Andrew L. , Martinez‐Lage, Maria , Mooradian, Meghan J. , Naidoo, Jarushka , Neilan, Tomas G. , Reardon, David A. , Rubin, Krista M., Santomasso, Bianca , Sullivan, Ryan J. , Woodman, Karin , Zubiri, Leyre , Louv, William C, Reynolds, Kerry L. , Amato, Anthony A. , Betof Warner, Allison , Dougan, Michael , Mooradian, Meghan J , Naidoo, Jarushka , Sullivan, Ryan J , Zubiri, Leyre , Kolb, Noah A , Clardy, Stacey L , Dubey, Divyanshu , Martinez-Lage, Maria , Cho, Tracey A , Brastianos, Priscilla K. , Cohen, Justine Vanessa , Gelfand, Jeffrey M. , Wang, Nancy

Mayo Clinic

Journal for ImmunoTherapy of Cancer | July 19, 2021 | Volume: 9 | Issue: 7 | Pages: e002890

10.1136/jitc-2021-002890 | PMID 34281989 Get It

Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence of 1%–12% and a high fatality rate relative to other irAEs. Lack of standardized disease definitions and accurate phenotyping leads to syndrome misclassification and impedes development of evidence-based treatments and translational research. The objective of this study was to develop consensus guidance for an approach to irAE-Ns including disease definitions and severity grading. A working group of four neurologists drafted irAE-N consensus guidance and definitions, which were reviewed by the multidisciplinary Neuro irAE Disease Definition Panel including oncologists and irAE experts. A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two meetings to discuss areas of controversy. Panelists rated content for usability, appropriateness and accuracy on 9-point scales in electronic surveys and provided free text comments. Aggregated survey responses were incorporated into revised definitions. Consensus was based on numeric ratings using the RAND/University of California Los Angeles (UCLA) Appropriateness Method with prespecified definitions. 27 panelists from 15 academic medical centers voted on a total of 53 rating scales (6 general guidance, 24 central and 18 peripheral nervous system disease definition components, 3 severity criteria and 2 clinical trial adjudication statements); of these, 77% (41/53) received first round consensus. After revisions, all items received second round consensus. Consensus definitions were achieved for seven core disorders: irMeningitis, irEncephalitis, irDemyelinating disease, irVasculitis, irNeuropathy, irNeuromuscular junction disorders and irMyopathy. For each disorder, six descriptors of diagnostic components are used: disease subtype, diagnostic certainty, severity, autoantibody association, exacerbation of pre-existing disease or de novo presentation, and presence or absence of concurrent irAE(s). These disease definitions standardize irAE-N classification. Diagnostic certainty is not always directly linked to certainty to treat as an irAE-N (ie, one might treat events in the probable or possible category). Given consensus on accuracy and usability from a representative panel group, we anticipate that the definitions will be used broadly across clinical and research settings.
PRRX1–NCOA1‐rearranged fibroblastic tumour: a clinicopathological, immunohistochemical and molecular genetic study of six cases of a potentially under‐recognised, distinctive mesenchymal tumour
Dermawan, Josephine K. , Azzato, Elizabeth M. , Thangaiah, Judith Jebastin, Gjorgova‐Gjeorgievski, Sandra, Folpe, Andrew L. , Fritchie, Karen , Jebastin Thangaiah, Judith, Folpe, Andrew , Agaimy, Abbas , Dermawan, Josephine K T , Rubin, Brian P.

Mayo Clinic

Histopathology | July 17, 2021 | Volume: 79 | Issue: 6 | Pages: 997-1003

10.1111/his.14454 | PMID 34272753 Get It

AimsPRRX1–NCOA1‐rearranged fibroblastic tumour is a recently described, rare mesenchymal tumour. Only four cases have been previously reported. The aim of this article is to report six additional cases of this unusual mesenchymal neoplasm, with an emphasis on its differential diagnosis.Methods and resultsThe six cases were from three females and three males (age, 20–49 years; median, 42 years). Three tumours were located on the abdominal wall; two from the shoulder/axillary areas, and one on the lateral hip. All presented as slow‐growing subcutaneous nodules, ranging from 26 to 55 mm (median, 40 mm). The tumours consisted of circumscribed, variably cellular nodules composed of relatively bland plump spindled to epithelioid cells arranged singly, in cords, and occasionally in nests, embedded in hyalinised and collagenous stroma. Small hypocellular myxoid zones with ropey collagen fibres were present, as were irregularly dilated, gaping, crescent‐shaped or staghorn‐like thin‐walled vessels, best appreciated at the periphery. Immunohistochemistry for CD34, S100, MUC4 and STAT6 was consistently negative. RNA‐sequencing revealed PRRX1–NCOA1 fusions in all cases. Of the four cases with limited follow‐up (1.5–4 months), none recurred following local surgical excision.ConclusionsThe morphological features of PRRX1–NCOA1‐rearranged fibroblastic tumour overlap with those of RB1‐deficient soft‐tissue tumours, solitary fibrous tumour, and low‐grade fibromyxoid sarcoma/sclerosing epithelioid fibrosarcoma. This differential diagnosis can be resolved with a combination of careful morphological study and the application of a panel of immunostains, although molecular genetic study is most definitive. The natural history of PRRX1–NCOA1‐rearranged fibroblastic tumour appears to be quite favourable, although longer‐term study of a larger number of cases is warranted.
Timing of Flap Coverage With Respect to Definitive Fixation in Open Tibia Fractures
Kuripla, Casey, Foote, Clary J. , Koh, Justin , Sems, Andrew, Shamaa, Tayseer , Sorg, Debra, Streufert, Benjamin D. , Spitler, Clay A. , McGowan, Brian, Weinlein, John C., Cannada, Lisa K. , Charlu, Jonathan, Wagstrom, Emily, Westberg, Jerald R., Cortez, Abigail , Marcantonio, Andrew , Soles, Gillian , Lipof, Jason S. , Tornetta, Paul , Sems, Andrew, Vallier, Heather A. , Mir, Hassan R. , Mullis, Brian , Morshed, Saam , Krause, Peter C.

Mayo Clinic

Journal of Orthopaedic Trauma | July 16, 2021 | Volume: 35 | Issue: 8 | Pages: 430-436

10.1097/bot.0000000000002033 | PMID 34267149 Get It

Objectives: We conducted a large, U.S wide, observational study of type III tibial fractures, with the hypothesis that delays between definitive fixation and flap coverage might be a substantial modifiable risk factor associated with nosocomial wound infection. Design: A retrospective analysis of a multicenter database of open tibial fractures requiring flap coverage. Setting: Fourteen level-1 trauma centers across the United States. Patients: Two hundred ninety-six (n = 296) consecutive patients with Gustilo III open tibial fractures requiring flap coverage at 14 trauma centers were retrospectively analyzed from a large orthopaedic trauma registry. We collected demographics and the details of surgical care. We investigated the patient, and treatment factors leading to infection, including the time from various points in care to the time of soft-tissue coverage. Intervention: Delay definitive fixation and flap coverage in tibial type III fractures. Main Outcome Measurements: (1) Results of multivariate regression with time from injury to coverage, debridement to coverage, and definitive fixation to coverage in the model, to determine which delay measurement was most associated with infection. (2) A second multivariate model, including other factors in addition to measures of flap delay, to provide the estimate between delay and infection after adjustment for confounding. Results: Of 296 adults (227 M: 69 F) with open Gustilo type III tibial fractures requiring flap coverage, 96 (32.4%) became infected. In the multivariate regression, the time from definitive fixation to flap coverage was most predictive of subsequent wound infection (odds ratio 1.04, 95% confidence interval 1.01 to 1.08, n = 260, P = 0.02) among the time measurements. Temporary internal fixation was not associated with an increased risk of infection in both univariate (P = 0.59) or multivariate analyses (P = 0.60). Flap failure was associated with the highest odds of infection (odds ratio 6.83, 95% confidence interval 3.26 to 14.27, P < 0.001). Conclusion: Orthoplastic teams that are dedicated to severe musculoskeletal trauma, that facilitate coordination of definitive fixation and flap coverage, will reduce the infection rates in Gustilo type III tibial fractures. Level of Evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
Civilian walking blood bank emergency preparedness plan
Holcomb, John B. , Spinella, Philip C. , Apelseth, Torunn Oveland , Butler, Frank K., Cannon, Jeremy W. , Cap, Andrew P., Corley, Jason B., Doughty, Heidi , Fitzpatrick, Michael H., Goldkind, Sara F., Gurney, Jennifer M. , Homer, Mary J. , Jenkins, Donald H. , Moore, Eugene, Ness, Paul M., Schreiber, Martin A. , Shinar, Eilat , Sloan, Steve, Stubbs, James R. , Taylor, Audra L., Ward, Kevin R. , Waltman, Elizabeth, Yazer, Mark H. , Jansen, Jan O , Strandenes, Geir , Stubbs, James R , Yazer, Mark , Spinella, Philip C , Apelseth, Torunn , Holcomb, John B , Cap, Andrew P., Ilstrup, Sarah J. , Jansen, Jan O. , Marques, Marisa B. , O’Connor, Kevin C. , Strandenes, Geir

Mayo Clinic

Transfusion | July 16, 2021 | Volume: 61 | Issue: S1 | Pages: No page available

10.1111/trf.16458 | PMID 34269450 Get It

Abstract Background The current global pandemic has created unprecedented challenges in the blood supply network. Given the recent shortages, there must be a civilian plan for massively bleeding patients when there are no blood products on the shelf. Recognizing that the time to death in bleeding patients is less than 2 h, timely resupply from unaffected locations is not possible. One solution is to transfuse emergency untested whole blood (EUWB), similar to the extensive military experience fine‐tuned over the last 19 years. While this concept is anathema in current civilian transfusion practice, it seems prudent to have a vetted plan in place. Methods and Materials During the early stages of the 2020 global pandemic, a multidisciplinary and international group of clinicians with broad experience in transfusion medicine communicated routinely. The result is a planning document that provides both background information and a high‐level guide on how to emergently deliver EUWB for patients who would otherwise die of hemorrhage. Results and Conclusions Similar plans have been utilized in remote locations, both on the battlefield and in civilian practice. The proposed recommendations are designed to provide high‐level guidance for experienced blood bankers, transfusion experts, clinicians, and health authorities. Like with all emergency preparedness, it is always better to have a well‐thought‐out and trained plan in place, rather than trying to develop a hasty plan in the midst of a disaster. We need to prevent the potential for empty shelves and bleeding patients dying for lack of blood.
Spectrum bias in algorithms derived by artificial intelligence: a case study in detecting aortic stenosis using electrocardiograms
Shelly-Cohen, Michal, Attia, Itzhak Z, Friedman, Paul A. , Oh, Jae K. , López-Jiménez, Francisco , Lopez-Jimenez, Francisco , Tseng, Andrew S. , Attia, Itzhak Z, Noseworthy, Peter A.

Mayo Clinic

European Heart Journal - Digital Health | July 14, 2021 | Volume: 2 | Issue: 4 | Pages: 561-567

10.1093/ehjdh/ztab061 | PMID 36713099 Get It

Abstract Aims Spectrum bias can arise when a diagnostic test is derived from study populations with different disease spectra than the target population, resulting in poor generalizability. We used a real-world artificial intelligence (AI)-derived algorithm to detect severe aortic stenosis (AS) to experimentally assess the effect of spectrum bias on test performance. Methods and results All adult patients at the Mayo Clinic between 1 January 1989 and 30 September 2019 with transthoracic echocardiograms within 180 days after electrocardiogram (ECG) were identified. Two models were developed from two distinct patient cohorts: a whole-spectrum cohort comparing severe AS to any non-severe AS and an extreme-spectrum cohort comparing severe AS to no AS at all. Model performance was assessed. Overall, 258 607 patients had valid ECG and echocardiograms pairs. The area under the receiver operator curve was 0.87 and 0.91 for the whole-spectrum and extreme-spectrum models, respectively. Sensitivity and specificity for the whole-spectrum model was 80% and 81%, respectively, while for the extreme-spectrum model it was 84% and 84%, respectively. When applying the AI-ECG derived from the extreme-spectrum cohort to patients in the whole-spectrum cohort, the sensitivity, specificity, and area under the curve dropped to 83%, 73%, and 0.86, respectively. Conclusion While the algorithm performed robustly in identifying severe AS, this study shows that limiting datasets to clearly positive or negative labels leads to overestimation of test performance when testing an AI algorithm in the setting of classifying severe AS using ECG data. While the effect of the bias may be modest in this example, clinicians should be aware of the existence of such a bias in AI-derived algorithms.
The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice
Nadauld, Lincoln , McDonnell, Charles H. , Beer, Tomasz M. , Liu, Minetta C. , Klein, Eric A. , Hudnut, Andrew , Whittington, Richard, Oxnard, Geoffrey R. , Lipson, Jafi A. , Lopatin, Margarita , Shaknovich, Rita , Chung, Karen , Fung, Eric T. , Marinac, Catherine R. , Lipson, Jafi , Chung, Karen C , Marinac, Catherine R , Klein, Eric A , Beer, Tomasz M , Taylor, Bruce , Schrag, Deborah

Mayo Clinic

Cancers | July 13, 2021 | Volume: 13 | Issue: 14 | Pages: 3501

10.3390/cancers13143501 | PMID 34298717 Get It

To examine the extent of the evaluation required to achieve diagnostic resolution and the test performance characteristics of a targeted methylation cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test, ~6200 participants ≥50 years with (cohort A) or without (cohort B) ≥1 of 3 additional specific cancer risk factors will be enrolled in PATHFINDER (NCT04241796), a prospective, longitudinal, interventional, multi-center study. Plasma cfDNA from blood samples will be analyzed to detect abnormally methylated DNA associated with cancer (i.e., cancer “signal”) and a cancer signal origin (i.e., tissue of origin). Participants with a “signal detected” will undergo further diagnostic evaluation per guiding physician discretion; those with a “signal not detected” will be advised to continue guideline-recommended screening. The primary objective will be to assess the number and types of subsequent diagnostic tests needed for diagnostic resolution. Based on microsimulations (using estimates of cancer incidence and dwell times) of the typical risk profiles of anticipated participants, the median (95% CI) number of participants with a “signal detected” result is expected to be 106 (87–128). Subsequent diagnostic evaluation is expected to detect 52 (39–67) cancers. The positive predictive value of the MCED test is expected to be 49% (39–58%). PATHFINDER will evaluate the integration of a cfDNA-based MCED test into existing clinical cancer diagnostic pathways. The study design of PATHFINDER is described here.
Genome-wide interaction analysis identified low-frequency variants with sex disparity in lung cancer risk
Li, Yafang , Xiao, Xiangjun , Byun, Jinyoung , Cheng, Chao , Bossé, Yohan , McKay, James , Lam, Stephen , Tardón, Adonina , Chen, Chu , Landi, Maria Teresa , Wichmann, Erich, Goodman, Gary, Field, John K. , Shete, Sanjay , Melander, Olle , Andrew, Angeline S. , Grankvist, Kjell , Johansson, Mikael , Caporaso, Neil E. , Aldrich, Melinda C. , Schwartz, Ann G. , Gorlov, Ivan P. , Purrington, Kristen S. , Yang, Ping , Bailey‐Wilson, Joan E. , Liu, Yanhong , Mandal, Diptasri , Gaba, Colette , Brennan, Paul , Cheng, Chao , Wilson, Richard K , Field, John K , Tardón, Adonina , Bossé, Yohan , Grankvist, Kjell , Purrington, Kristen S , Byun, Jinyoung , Li, Jianrong , Albanes, Demetrius , Bojesen, Stig E. , Johansson, Mattias , Risch, Angela , Bickeböller, Heike , Christiani, David C. , Rennert, Gad , Arnold, Susanne M. , Marchand, Loı̈c Le , Brunnström, Hans , Liu, Geoffrey , Hung, Rayjean J. , Kiemeney, Lambertus A. , Shen, Hongbing , Sun, Ryan , Zienolddiny, Shanbeh , Teare, M. Dawn , Hong, Yun‐Chul , Davies, Michael P.A. , Lazarus, Philip J. , Schabath, Matthew B. , Han, Younghun , Pinney, Susan M. , Willey, James C. , Amos, Christopher I.

Mayo Clinic

No container title available | July 13, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-647012/v1 Get It

Abstract There is growing evidence showing that sex disparity in lung cancer risk cannot be fully explained by sex differences in smoking behavior, implying existence of genetic and molecular basis for sex disparity in lung cancer development. However, the information about sex dimorphism in lung cancer risk is quite limited despite the great success in lung cancer association studies. By adopting a stringent two-stage analysis strategy, we performed a genome-wide gene-sex interaction analysis using genotype from a lung cancer cohort including ~ 47,000 individuals with European ancestry. Three low-frequency variants (minor allele frequency < 0.05), rs17662871 (OR=0.71, p=4.29x10-8); rs79942605 (OR=2.17, p=2.81x10-8); and rs208908 (OR=0.70, p=4.54x10-8), were identified with different risk effect of lung cancer between men and women. Further eQTL and functional annotation analysis suggested rs208908 affect lung cancer risk through differential regulation of CXADR (Coxsackie Virus And Adenovirus Receptor) gene expression in lung tissues between men and women. Our study is one of the first studies to provide novel insights about the genetic and molecular basis for sex disparity in lung cancer development.
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Walker, Alison R. , Marcucci, Guido , Yin, Jun , Blum, William , Kohlschmidt, Jessica, Mrózek, Krzysztof , Carroll, Andrew J. , Eisfeld, Ann-Kathrin, Kolitz, Jonathan E. , Thakuri, Mohan C., Sutamtewagul, Grerk , Vij, Ravi , Byrd, John C. , Bloomfield, Clara D. , Stone, Richard M. , Byrd, John C. , Jacobson, Sawyer , Sutamtewagul, Grerk , Larson, Richard A , Stock, Wendy , Eisfeld, Ann‐Kathrin , Wang, Eunice S. , Stuart, Robert K. , Larson, Richard A. , Byrd, John C

Mayo Clinic

Blood Advances | July 12, 2021 | Volume: 5 | Issue: 13 | Pages: 2775-2787

10.1182/bloodadvances.2021004233 | PMID 34251414 Get It

Abstract Overexpression of B-cell leukemia/lymphoma 2 (BCL2) renders acute myeloid leukemia (AML) cells resistant to chemotherapy and has been associated with unfavorable outcomes. Oblimersen (G3139) is a phosphorothioate 18-mer antisense oligonucleotide directed against the first 6 BCL2 codons. In a phase 1 study of AML patients treated with G3139, cytarabine, and daunorubicin induction with cytarabine consolidation, no antisense-related toxicity was reported, and BCL2 downregulation occurred in patients achieving complete remission. In this phase 3 trial, untreated older AML patients were randomized to cytarabine (100 mg/m2 per day on days 4-10) and daunorubicin (60 mg/m2 per day on days 4-6) followed by cytarabine consolidation (2000 mg/m2 per day on days 4-8) with (arm A) or without (arm B) G3139 (7 mg/m2 per day on days 1-10 [induction] or days 1-8 [consolidation]). A total of 506 patients were enrolled. No differences in toxicity were observed between arms. Estimated overall survival (OS) at 1 year was 43% for arm A and 40% for arm B (1-sided log rank P = .13), with no differences in disease-free (DFS; P = .26) or event-free survival (P = .80). Subgroup analyses showed patients age &lt;70 years in arm A had improved OS by 1 month vs those in arm B (P = .04), and patients with secondary AML in arm A had better DFS vs those in arm B (P = .04). We conclude that addition of G3139 to chemotherapy failed to improve outcomes of older AML patients. However, more effective means of inhibiting BCL2 are showing promising results in combination with chemotherapy in AML. This trial was registered at www.clinicaltrials.gov as #NCT00085124.
Effects of Experimental Sleep Restriction on Ambulatory and Sleep Blood Pressure in Healthy Young Adults: A Randomized Crossover Study
Covassin, Naima , Bukartyk, Jan , Singh, Prachi , Calvin, Andrew D. , Louis, Erik K. St. , Somers, Virend K. , St Louis, Erik K, Somers, Virend K. , St Louis, E K , Singh, Prachi , Calvin, Andrew D

Mayo Clinic

Hypertension | July 12, 2021 | Volume: 78 | Issue: 3 | Pages: 859-870

10.1161/hypertensionaha.121.17622 | PMID 34247512 Get It

Although insufficient sleep is associated with increased cardiovascular risk, evidence of a causal relationship is lacking. We investigated the effects of prolonged sleep restriction on 24-hour ambulatory blood pressure (BP) and other cardiovascular measures in 20 healthy young participants (aged 23.4±4.8 years, 9 females), who underwent a randomized, controlled, crossover, 16-day inpatient study consisting of 4 days of acclimation, 9 days of sleep restriction (4 hours of sleep/night) or control sleep (9 hours), and 3 days of recovery. Subjects consumed a weight maintenance diet with controlled nutrient composition throughout. A 24-hour BP (primary outcome) and cardiovascular biomarkers were measured repeatedly. Polysomnographic monitoring was continuous. Comparing sleep restriction versus control sleep, 24-hour mean BP was higher (adjusted mean difference, day 12: 2.1 mm Hg [95% CI, 0.6–3.6], corrected P =0.016), endothelial function was attenuated ( P <0.001), and plasma norepinephrine increased ( P =0.011). Despite increased deep sleep, BP was elevated while asleep during sleep restriction and recovery. Post hoc analysis revealed that 24-hour BP, wakefulness, and sleep BP increased during experimental and recovery phases of sleep restriction only in women, in whom 24-hour and sleep systolic BP increased by 8.0 (5.1–10.8) and 11.3 (5.9–16.7) mm Hg, respectively (both P <0.001). Shortened sleep causes persistent elevation in 24-hour and sleep-time BP. Pressor effects are evident despite closely controlled food intake and weight, suggesting that they are primarily driven by the shortened sleep duration. BP increases are especially striking and sustained in women, possibly suggesting lack of adaptation to sleep loss and thus greater vulnerability to its adverse cardiovascular effects.